AI Reshaping FDA Compliance in GMP Inspection Strategy and Audit Prioritization
George Kwiecinski highlighted that FDA inspection and audit capacity remains finite, and this limitation drives a more structured approach to supplier selection. He emphasized that companies must now rely on documented, technology-supported methodologies when they prioritize audits or reinspection activities. As a result, organizations increasingly integrate modern tech stacks into quality systems, and they use them to improve traceability and decision-making under QMSR expectations.
Moreover, he explained that regulators now expect stronger internal audit documentation. Therefore, companies must reassess how they select suppliers and how they justify oversight decisions. This change reflects a broader shift toward risk-based compliance models, where organizations align inspection strategies with operational constraints and regulatory expectations.
FDA Regulatory Compliance AI and Growing Compliance Risks in Global Pharma Supply Chains
Kwiecinski stated that the core compliance risk profile in pharmaceutical supply chains does not fundamentally change. However, context around these risks evolves rapidly as new technologies enter regulated workflows. He noted that quality unit performance remains a central driver of FDA citations, while consistent application of safety and efficacy standards across third-party vendors continues to define inspection outcomes.
In addition, he stressed that organizations face increasing pressure to maintain uniform compliance across distributed supply networks. As supply chains expand globally, companies must ensure that regulatory expectations remain consistent across all partners. This becomes even more critical as AI tools begin to influence decision-making and documentation processes.
AI Reshaping FDA Regulatory Compliance as FDA Increases Scrutiny of AI in Pharma
Kwiecinski also addressed the growing role of AI in regulatory intelligence and compliance workflows. He noted that FDA scrutiny of AI usage has already increased, including references to AI-generated content in regulatory correspondence. In one example, AI-generated documentation appeared directly in FDA warning letter discussions, which signals rising attention from regulators.
Furthermore, he explained that internal research shows a steady increase in FDA documents referencing AI over the past several years. According to this trend, regulators increasingly integrate AI considerations into their oversight framework. Consequently, pharmaceutical companies must carefully evaluate how they deploy AI in regulatory processes and ensure that they document and defend those decisions clearly.
FDA Regulatory Compliance AI and the Future of Risk-Based Supplier Oversight and Governance Models
Finally, Kwiecinski emphasized that companies must respond to these developments with a risk-based governance approach. He advised that organizations should first recognize the accelerating regulatory changes and then evaluate their internal tech stacks. If companies use AI in quality or regulatory workflows, they must ensure transparent documentation of those decisions.
He added that AI investment decisions must remain grounded in business value and controlled implementation. If a tool improves efficiency and operates within validated frameworks, companies can justify its adoption. However, the most important factor remains risk governance, especially as FDA scrutiny of AI-assisted decision-making continues to grow across pharmaceutical compliance systems.
Source: pharmtech.com